12 July 2007



Intrinsyc Software International Inc.

ICS: TSX: C\$0.75

SPECULATIVE BUY

Target: C\$1.75

Peter Misek 1.416.869.7920

peter.misek@canaccordadams.com

Eyal Ofir, CFA 1.416.869.7215

eyal.ofir@canaccordadams.com

Sameet Kanade 1.416.869.7294

sameet.kanade@canaccordadams.com


COMPANY STATISTICS:

52-week Range:	\$0.34-0.77
Avg. Daily Vol. (000):	196.8
Market Capitalization (M):	\$87.3
Shares Out. (M) basic:	116.4
Shares Out. (M) fd:	116.4

EARNINGS SUMMARY:

FYE Aug	2005A	2006A	2007E	2008E	2009E
Revenue (M):	17.5	18.7	19.7	29.7	69.1
EV/Sales:	3.8x	3.5x	3.3x	2.2x	1.0x
EPS:	(0.11)	(0.24)	(0.19)	(0.10)	0.09
P/E:	NM	NM	NM	NM	8.0x

SHARE PRICE PERFORMANCE:



COMPANY SUMMARY:

Intrinsyc Software is a mobility software and services company, based in Vancouver, BC. The company's technologies and services enable companies to identify and create solutions to make mobile devices connect and work. Intrinsyc creates and licenses mobile and embedded software products to OEMs, as well as a suite of server-based interoperability solutions. Additionally, the company provides engineering services to support these products.

All amounts in C\$ unless otherwise noted.

Technology -- Software and Services

COMPANY REMAINS ON TRACK

Event

Intrinsyc reported Q3 results which were slightly higher than our estimates on the top-line and in line on an adjusted EPS basis. Revenue for the quarter was reported at C\$5.1 million compared to our estimate of C\$5.0 million. EPS was reported at C\$(0.05), but after adjusting for foreign-exchange losses and taxes was C\$(0.04), in line with our estimate.

Impact

Slightly positive. On the macro front, Intrinsyc continues to make solid progress positioning itself in the high growth mobile OS market and provided additional colour on its pipeline of opportunities. The company has identified 30 prospects for the Soleus software platform, and management is currently in discussions with more than 15 of these potential customers. This bodes well for the company into F08 and F09; hence, we have not changed our F08 and F09 estimates.

Action

Overall, our core thesis remains valid as the outlook provided by management confirms that the company is on track to gain additional platform and design wins and translate these contracts into material recurring revenue streams. We reiterate our SPECULATIVE BUY recommendation and C\$1.75 price target, based on our DCF analysis.

Valuation

Intrinsyc trades at a discount to peers on an F08 EV/Sales basis trading at 2.2 times, well below the industry average of 3.9 times. We believe the company should be trading at higher multiples than the peer average due to its impressive growth potential in F08 and beyond.

Canaccord Adams is the global capital markets group of Canaccord Capital Inc. (CCI: TSX|AIM)



Q3/F07 results

Intrinsyc reported Q3 results which were slightly higher than our estimates on the top-line and in line on an adjusted EPS basis. Revenue for the quarter was reported at C\$5.1 million compared to our estimate of C\$5.0 million. EPS was reported at C\$(0.05), but after adjusting for foreign-exchange losses and taxes was C\$(0.04), in line with our estimate.

Figure 1: Q3/F07 Results

(C\$ millions)	Q3/F07A	CA Q3/F07E	B/(W)	Q2/F07A	Q3/F06A	% Change Q/Q	% Change Y/Y
Revenue	5.1	5.0	0.1	5.0	4.4	1.5%	16.5%
Gross Profit % of Revenue	2.6 51.8%	2.4 48.0%	0.2	2.5 49.3%	1.5 35.2%	6.7%	71.3%
Total Op Ex % of Revenue	6.6 128.3%	6.2 122.9%	0.4	6.8 135.7%	5.7 129.7%	-4.1%	15.2%
EBITDA % of Revenue	-3.7 -72.5%	-3.6 -71.3%	-0.1	-4.1 -82.2%	-3.9 -89.6%	-10.5%	-5.8%
GAAP Net Income % of Revenue	-4.4 -85.7%	-3.8 -75.8%	-0.6	-4.2 -84.3%	-4.7	3.2%	-6.8%
GAAP EPS - diluted Adjusted EPS - diluted	(0.05) (0.04)	(0.04)	0.0	(0.05) (0.05)	(0.06) (0.06)	-5.8% -17.3%	-23.7% -32.9%

Source: Canaccord Adams, Company reports,

Pipeline update

On the conference call, management provided additional colour in regard to its current pipeline of opportunities and recent wins. The company has identified 30 prospects for the Soleus software platform, and management is currently in discussions with more than 15 of these potential customers. While specific details were not provided, management noted that a number of companies in the pipeline focus on the PND segment and multimedia oriented handsets. In our opinion, the company is currently in discussion with a large OEM/ODM that is looking to enter the mid-tier handset market utilizing a Microsoft-based software platform. We believe that this vendor may ramp rapidly over the next 12 months.

Management highlighted that discussions can vary from three to six months and, once a licensing agreement is in place, product shipment can take anywhere from nine to 12 months to start ramping. The company also provided insight into recent wins. In Q4/F07 management expects that a vendor will begin to ship devices into field trials, and full commercial shipments will begin sometime in Q1/F08 and ramp throughout the year.

Soleus update

The following are key highlights provided by management pertaining to Soleus:

• In line with management's strategy of advancing the Soleus software platform to meet customer demands and expand the addressable market, the company intends to launch the next version of Soleus towards the end of 2007 (Soleus V1.01). V1.01 will incorporate additional aspects related to telephony and IP.



- The company has continued to invest resources in the development and marketing of the Soleus software platform. YTD investment in R&D and S&M expenses related to Soleus is approximately C\$10.1 million, or 66.3% of total YTD revenue.
- The headcount has remained relatively flat on a Y/Y basis at 220; however, management has reallocated staff to the Soleus deployment from the ESG segment. In addition, the company has hired additional personnel with key industry experience that management believes will be able to help in achieving additional traction for Soleus in the marketplace.
- Management has initiated steps to establish and expand sales presence in key markets. As a result, the company has opened offices in Washington DC, Taiwan, Eastern Canada and California.

Figure	2.	Salaus	expense	analysis

(C\$ '000)	30-Nov-05	28-Feb-06	31-May-06	31-Aug-06	30-Nov-06	28-Feb-07	31-May-07
Soleus related R&D and S&M	1,540	2,510	2,930	3,580	3,370	3,800	3,300
Sequential growth		63.0%	16.8%	22.3%	-6.0%	12.9%	-13.2%
as % of revenue	33.8%	52.4%	66.8%	72.8%	67.1%	75.5%	64.6%

Source: Company reports, Canaccord Adams

Cash and cash flow

As expected, free cash flow was negative for the quarter. Intrinsyc recorded free cash flow in the quarter of (C\$2.8 million), compared to (C\$3.2 million) in Q2/F07 and (C\$3.5 million) in Q3/F06. This is better than we anticipated, primarily due to the lower than expected capital expenditures and an unanticipated accretion and amortization adjustment of long-term debt. Cash balances at the end of the quarter totaled C\$21.4 million, up from C\$5.9 million the previous quarter and C\$5 million Y/Y, due to the recent equity issue. Accounts receivables equaled C\$3 million for the quarter, down C\$1.0 million Q/Q and \$0.5 million Y/Y. Finally, prepaid expenses were C\$0.3 million for the quarter, down almost C\$0.1 million sequentially and up C\$0.1 million from the prior year.

Guidance

Management announced that a number of moves have been made to align the operations more closely with the firm's strategic plan. These included:

- Winding down a hardware business;
- Closing an engineering services office in Singapore; and
- Redirecting sales and marketing resources away from the embedded business into wireless opportunities.

These actions are expected to have a top line impact to the Q4/F07 results. Management provided guidance of a 10-20% sequential revenue decline for Q4. The company did not provide guidance beyond Q4/F07.

Estimate revisions

In light of management providing top line guidance expectations for Q4, we have adjusted our estimates going forward to incorporate the closure of the Singapore services office and have accelerated our expectation of the company exiting the hardware business. For



Q4/F07 our revenue expectation declines from C\$5.5 million to C\$4.6 million, while our EPS estimate stays flat. For F07, our revenue expectations decline by C\$0.9 million to C\$19.7 million, while our EPS declines by a penny as the Q3 results flow through. While we have not changed our F08 and F09 estimates, we have changed the quarterly skew of the F08 revenue levels to be more backend loaded. We will revisit our estimates as management provides further updates and additional wins are announced.

Figure 3: Estimate revisions								
	Q4/F07	F07	F08	F09				
Revenue (M)	•							
Revised	4.6	19.7	29.7	69.1				
Original	5.5	20.6	29.7	69.1				
Adjusted EPS								
Revised	(0.04)	(0.19)	(0.10)	0.09				
Original	(0.04)	(0.18)	(0.10)	0.09				

Source: Canaccord Adams

Outlook and recommendation

Our thesis is predicated on several key factors, which remain valid. These include: (i) The size and growth of the addressable market, driven by increased convergence of functionality within handsets; (ii) our belief in the credibility of the core management team which is comprised of seasoned professionals from specific industry verticals; and (ii) competitive positioning of the Soleus software platform, as an effective and viable alternative for OEMs and ODMs. We believe that the company's association with Microsoft serves as a very strong support mechanism in achieving design wins.

In our opinion, the outlook provided by management confirms that the company is on track to gain additional platform and design wins and translating these contracts into material recurring revenue streams. We believe that this growth will translate into higher valuations; and hence superior returns for investors. Hence, we reiterate our SPECULATIVE BUY recommendation and C\$1.75 price target, based on our DCF analysis.

Valuation

Intrinsyc trades at a discount to peers on an F08 EV/Sales basis trading at 2.2 times, well below the industry average of 3.9 times. We believe the company should be trading at higher multiples than the peer average due to its impressive growth potential in F08 and beyond.



Figure 4: Comparables

					Revenue			EPS		EV/S	Sales	P	P/E
Company	Ticker	Exchange	Last	F07	F08	Growth	F07	F08	Growth	F07	F08	F07	F08
Access	4813	: TSE	355,000	34,757	39,195	13%	-30,075	3,024	-110%	4.0	3.5	NM	117.4
Aplix	3727	: TSE	154,000	6,174	6,756	9%	-76,011	6,137	-108%	2.5	2.3	NM	25.1
Trolltech	TROLL	: OS	10.80	240.9	340.1	41%	-0.67	-0.19	NM	2.2	1.5	NM	NM
Call Genie	GNE.	:V	\$2.39	2.3	19.0	NM	-0.08	0.08	NM	NM	9.5	NM	NM
Red Hat	RHT	:N	\$21.26	488.0	608.0	25%	0.66	0.83	26%	7.8	6.2	32.2	25.6
Research In Motion	RIMM	:Q	\$211.07	4,786.4	7,015.0	47%	5.18	7.59	47%	8.1	5.5	40.7	27.8
Wind River	WIND	:Q	\$10.40	328	371	13%	0.32	0.51	59%	2.4	2.1	32.5	20.4
Zamano	ZMNO	:L	29.00	20	25	23%	0.04	0.05	18%	1.0	0.8	11.1	9.3
Zi Corp.	ZICA	:Q	\$1.14	12	15	24%	-0.09	-0.01	NM	4.1	3.3	NM	NM
Average						24%			-11%	4.0	3.9	29.1	37.6
Median						24%			22%	3.2	3.3	32.4	25.4
Intrinsyc*	ICS	:T	\$0.75	20	30	50%	-0.19	-0.10	90%	3.3	2.2	NM	NM
Intrinsyc*	ICS	:T	\$1.75	20	30	50%	-0.19	-0.10	90%	9.2	6.1	NM	NM

Source: Company reports, Bloomberg, Canaccord Adams estimates

Investment risks

The main risks to our outlook include the competitive environment intensifying, design wins take longer than expected to close, design wins to not translate into material revenue due to failed device launches, ESG division revenue erosion, and key management leaving the firm. Other risks include litigation, adverse F/X trends, slower-than-expected growth in the mobile device market, faster-than-expected ASP erosion at handset OEM/ODMs pressuring Intrinsyc's ASPs down significantly, and broader macroeconomic forces impacting the market.



APPENDIX: IMPORTANT DISCLOSURES

Analyst Certification:

Each authoring analyst of Canaccord Adams whose name appears on the front page of this investment research hereby certifies that (i) the recommendations and opinions expressed in this investment research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst's coverage universe and (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the investment research.

Site Visit:

An analyst has visited Intrinsyc's material operations in Vancouver, BC, Canada. No payment or reimbursement was received from the issuer for the related travel costs.

Distribution of Ratings: Global Stock Ratings (as of 29 June 2007)

	Coverage U	IB Clients	
Rating	#	%	%
Buy	302	55.6%	42.4%
Speculative Buy	68	12.5%	69.1%
Hold	147	27.1%	36.7%
Sell	26	4.8%	11.5%
	543	100.0%	

Canaccord Ratings System:

BUY: The stock is expected to generate risk-adjusted returns of over 10% during the next 12 months. **HOLD:** The stock is expected to generate risk-adjusted returns of 0-10% during the next 12 months. **SELL:** The stock is expected to generate negative risk-adjusted returns during the next 12 months. **NOT RATED:** Canaccord Adams does not provide research coverage of the relevant issuer.

"Risk-adjusted return" refers to the expected return in relation to the amount of risk associated with the designated investment or the relevant issuer.

Risk Qualifier:

SPECULATIVE: Stocks bear significantly higher risk that typically cannot be valued by normal fundamental criteria. Investments in the stock may result in material loss.

Canaccord Adams Research Disclosures as of 12 July 2007

Company	Disclosure
Intrinsyc Software International Inc.	1A, 2, 3, 7

- 1 The relevant issuer currently is, or in the past 12 months was, a client of Canaccord Adams or its affiliated companies. During this period, Canaccord Adams or its affiliated companies provided the following services to the relevant issuer:
 - A. investment banking services.
 - B. non-investment banking securities-related services.
 - C. non-securities related services.
- 2 In the past 12 months, Canaccord Adams or its affiliated companies have received compensation for Corporate Finance/Investment Banking services from the relevant issuer.
- In the past 12 months, Canaccord Adams or any of its affiliated companies have been lead manager, co-lead manager or co-manager of a public offering of securities of the relevant issuer or any publicly disclosed offer of securities of the relevant issuer or in any related derivatives.
- 4 Canaccord Adams acts as corporate broker for the relevant issuer and/or Canaccord Adams or any of its affiliated companies may have an agreement with the relevant issuer relating to the provision of Corporate Finance/Investment Banking services.
- **5** Canaccord Adams or any of its affiliated companies is a market maker or liquidity provider in the securities of the relevant issuer or in any related derivatives.
- In the past 12 months, Canaccord Adams, its partners, affiliated companies, officers or directors, or any authoring analyst involved in the preparation of this investment research has provided services to the relevant issuer for remuneration, other than normal course investment advisory or trade execution services.
- 7 Canaccord Adams intends to seek or expects to receive compensation for Corporate Finance/Investment Banking services from the relevant issuer in the next six months.
- 8 The authoring analyst, a member of the authoring analyst's household, or any individual directly involved in the preparation of this investment research, has a long position in the shares or derivatives, or has any other financial interest in the relevant issuer, the value of which increases as the value of the underlying equity increases.



9	The authoring analyst, a member of the authoring analyst's household, or any individual directly involved in
	the preparation of this investment research, has a short position in the shares or derivatives, or has any
	other financial interest in the relevant issuer, the value of which increases as the value of the underlying
	equity decreases.

- Those persons identified as the author(s) of this investment research, or any individual involved in the preparation of this investment research, have purchased/received shares in the relevant issuer prior to a public offering of those shares, and such person's name and details are disclosed above.
- A partner, director, officer, employee or agent of Canaccord Adams and its affiliated companies, or a member of his/her household, is an officer, or director, or serves as an advisor or board member of the relevant issuer and/or one of its subsidiaries, and such person's name is disclosed above.
- As of the month end immediately preceding the date of publication of this investment research, or the prior month end if publication is within 10 days following a month end, Canaccord Adams or its affiliate companies, in the aggregate, beneficially owned 1% or more of any class of the total issued share capital or other common equity securities of the relevant issuer or held any other financial interests in the relevant issuer which are significant in relation to the investment research (as disclosed above).
- As of the month end immediately preceding the date of publication of this investment research, or the prior month end if publication is within 10 days following a month end, the relevant issuer owned 1% or more of any class of the total issued share capital in Canaccord Adams or any of its affiliated companies.
- **14** Other specific disclosures as described above.

Canaccord Adams is the business name used by certain subsidiaries of Canaccord Capital Inc., including Canaccord Adams Inc., Canaccord Adams Limited, and Canaccord Adams, a division of Canaccord Capital Corporation. Clients of Canaccord Adams, in the past 12 months, may have been clients of Canaccord Capital Corporation, Canaccord Capital (Europe) Limited, Canaccord Capital Corporation USA Inc., and/or Adams Harkness Financial Group Ltd.

The authoring analysts who are responsible for the preparation of this investment research are employed by Canaccord Adams, a securities broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal (all Canada), Boston, New York, San Francisco (all US) and London (UK).

In the event that this is compendium investment research (covering six or more relevant issuers), Canaccord Adams and its affiliated companies may choose to provide specific disclosures of the subject companies by reference, as well as its policies and procedures regarding the dissemination of investment research. To access this material or for more information, please send a request to Canaccord Adams Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2 or disclosures@canaccordadams.com.

The authoring analysts who are responsible for the preparation of this investment research have received (or will receive) compensation based upon (among other factors) the Corporate Finance/Investment Banking revenues and general profits of Canaccord Adams. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Corporate Finance/Investment Banking activities, or to recommendations contained in the investment research. Canaccord Adams and its affiliated companies may have a Corporate Finance/Investment Banking or other relationship with the company that is the subject of this investment research and may trade in any of the designated investments mentioned herein either for their own account or the accounts of their customers, in good faith or in the normal course of market making. Accordingly, Canaccord Adams or their affiliated companies, principals or employees (other than the authoring analyst(s) who prepared this investment research) may at any time have a long or short position in any such designated investments, Related designated investments or in options, futures or other derivative instruments based thereon. Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. This investment research has been prepared in accordance with Canaccord Adams' policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Adams' policy is available upon request.

The information contained in this investment research has been compiled by Canaccord Adams from sources believed to be reliable, but (with the exception of the information about Canaccord Adams) no representation or warranty, express or implied, is made by Canaccord Adams, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Adams has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this investment research constitute Canaccord Adams' judgement as of the date of this investment research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.

Canaccord Adams salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this investment research. Canaccord Adams' affiliates, proprietary trading desk, and investing businesses may make investment decisions that are inconsistent with the





recommendations or views expressed in this investment research.

This investment research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this investment research may not be eligible for sale in some jurisdictions. This investment research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Adams, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this investment research.

For Canadian Residents:

This Investment Research has been approved by Canaccord Adams, a division of Canaccord Capital Corporation, which accepts responsibility for this Investment Research and its dissemination in Canada. Canadian clients wishing to effect transactions in any Designated Investment discussed should do so through a qualified salesperson of Canaccord Adams, a division of Canaccord Capital Corporation in their particular jurisdiction.

For United Kingdom Residents:

This Investment Research complies with of the Financial Services Authority's Handbook's chapter on Conduct of Business and is approved by Canaccord Adams Limited, which is regulated and authorized by the Financial Services Authority, in connection with its distribution in the United Kingdom. This material is not for distribution in the United Kingdom to private customers, as defined under the rules of the Financial Services Authority. Canaccord Adams Limited accepts responsibility for this Investment Research and its dissemination in the United Kingdom. The information contained in this Investment Research is only intended for distribution in the UK to persons who qualify as intermediate customers or market counterparties, as defined under the rules of the Financial Services Authority.

For United States Residents:

Canaccord Adams Inc., a US registered broker-dealer, accepts responsibility for this Investment Research and its dissemination in the United States. This Investment Research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any Designated Investment discussed should do so through a qualified salesperson of Canaccord Adams Inc..

For European Residents:

If this Investment Research is intended for disclosure in any jurisdiction other than the United Kingdom, the US or Canada, then the relevant rules and regulatory requirements of that jurisdiction will apply.

Additional information is available on request.

Copyright © Canaccord Adams, a division of Canaccord Capital Corporation 2007. – Member IDA/CIPF Copyright © Canaccord Adams Limited 2007. – Member LSE, regulated and authorized by the Financial Services Authority.

Copyright © Canaccord Adams Inc. 2007. - Member NASD/SIPC

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Adams, a division of Canaccord Capital Corporation, Canaccord Adams Limited, and Canaccord Adams Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.